(Q50306200)

2 March 2018

title

Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. (English)

1 reference

2 March 2018

0 references

1 reference

1 reference

8

1 reference

2 March 2018

author name string

Mahtab Asadabadi

1

1 reference

2 March 2018

Mohammad-Reza Mohammadi

2

1 reference

2 March 2018

Ahmad Ghanizadeh

3

1 reference

2 March 2018

Amirhossein Modabbernia

4

1 reference

2 March 2018

Mandana Ashrafi

5

1 reference

2 March 2018

Elmira Hassanzadeh

6

1 reference

2 March 2018

Saeedeh Forghani

7

1 reference

2 March 2018

publication date

11 July 2012

1 reference

2 March 2018

published in

Psychopharmacology

1 reference

2 March 2018

volume

225

1 reference

2 March 2018

issue

1

1 reference

2 March 2018

page(s)

51-59

1 reference

2 March 2018

https://scigraph.springernature.com/pub.10.1007/s00213-012-2796-8

exact match

0 references

cites work

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

A review of autism and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

The immune response in autism: a new frontier for autism research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Effect of pioglitazone treatment on behavioral symptoms in autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Immune dysfunction in autism: a pathway to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Immunological findings in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Differential monocyte responses to TLR ligands in children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Multiple pathways in prevention of immune-mediated brain disorders: Implications for the prevention of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Immune transcriptome alterations in the temporal cortex of subjects with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

The immune system's role in the biology of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Macrophage migration inhibitory factor and autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

A study of nuclear transcription factor-kappa B in childhood autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

The role of immune dysfunction in the pathophysiology of autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Immune involvement in schizophrenia and autism: etiology, pathology and animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

S-nitrosylation/activation of COX-2 mediates NMDA neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Neuroglial activation and neuroinflammation in the brain of patients with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Transcriptomic analysis of autistic brain reveals convergent molecular pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Low natural killer cell cytotoxic activity in autism: the role of glutathione, IL-2 and IL-15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Cerebrospinal fluid and serum markers of inflammation in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-012-2796-8

Macrophage migration inhibitory factor activates cyclooxygenase 2-prostaglandin E2 in cultured spinal microglia

21 January 2018

1 reference

12 December 2020

The immune system and schizophrenia. An integrative view.

1 reference

12 December 2020

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

1 reference

12 December 2020

Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages

1 reference

12 December 2020

10.1007/S00213-012-2796-8

Identifiers

DOI

1 reference

2 March 2018

1 reference

2 March 2018